News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antibe Therapeutics Inc. Reports Q1 2015 Interim Financial And Operating Results


8/28/2014 10:25:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE) filed its financial and operating results today for its fiscal quarter ended June 30, 2014.

Highlights for the quarter include:

* Conducted non-brokered private placements yielding gross proceeds of $1,244,560, which together with financings closed in fiscal Q4 2014, is sufficient to fund Phase I clinical trials for Antibe’s lead drug, ATB-346

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES